Right Target, Small Effect? Rethinking CNS - COYA THERAPEUTICS INC

Financial Performance:

• No specific financial metrics (revenue, earnings, margins, cash flow, debt) were disclosed as the discussion focuses on clinical-stage biotechnology companies (Leo Therapeutics and Koya) rather than mature commercial operations.
• Both companies are in pre-clinical or early clinical trial phases (Leo Phase 1b/2; Koya Phase 2), implying significant capital expenditure with no near-term commercial revenue.

Guidance and Future Outlook:

• Leo Therapeutics: Plans to complete non-human primate (NHP) data for shuttle technology this quarter; aims to initiate IND-enabling studies for MAPT (Tau) and APOE programs shortly; targeting open-label extension for LTX002 in ALS.
• Koya: On track to report top-line Phase 2 "All-Stars" data for ALS in Q2; initiated FDA approval process for FTD trial with initiation expected in 2027; potential for expansion into other neurodegenerative diseases pending positive data.
• Long-term Goal: Stabilization of disease progression rather than cure, specifically targeting newly diagnosed patients to maintain quality of life.

Business Segments and Product Lines:

• Leo Therapeutics:
  • LTX002 (ASO): Targets SPTLC1 enzyme to inhibit ceramide/sphingolipid synthesis; currently enrolling in Europe with robust preclinical NHP safety/efficacy; also has a brain-penetrant oral small molecule candidate targeting the same enzyme.
  • Shuttle Technology: Proprietary transferrin-based antibody-like shuttles for peripheral delivery of nucleic acids and antibodies across the blood-brain barrier; candidates in NHP for MAPT (sRNA) and APOE programs showing superior CNS knockdown vs. peripheral delivery.
• Koya:
  • COYA-302: Combination therapy of ultra-low-dose IL-2 (boosts Regulatory T-cells) and low-dose CTLA-4 (suppresses effector T-cells); designed to reverse T-cell dysfunction in inflammation-driven neurodegeneration.
  • Pipeline Extensions: Phase 2 ALS trial (All-Stars) includes stratification by NFL; FTD trial pending FDA approval; potential for APOE/antibody delivery via Leo's shuttle tech.

Market and Competitive Landscape:

• ALS Market: Current approved treatments (e.g., Tofersen, Darabom) are limited to specific genetic subpopulations (SOD1, FUS, SPTLC1) or show limited efficacy in broad sporadic populations (97-98% of cases).
• Competitive Advantage: Leo targets the broadly validated metabolic pathway of ceramide sphingolipids present in both rare genetic and sporadic ALS; Koya targets the inflammatory mechanism common to ALS, FTD, and Alzheimer's via T-reg modulation.
• Differentiation: Koya distinguishes its Phase 2 design by stratifying patients based on NFL biomarkers to exclude fast-progressors with irreversible axonal damage, addressing a common cause of prior trial failures.

Risks and Challenges:

• Clinical Failure Risk: High failure rate in ALS history; reliance on unproven mechanisms for broad sporadic populations.
• Biomarker Limitations: NFL is noted as a marker of axonal injury that may not track well with clinical progression in all contexts; reliance on alternative markers like oxidative stress.
• Delivery Challenges: Achieving deep CNS knockdown and avoiding off-target toxicity (e.g., reticulocyte drops) with antibody shuttle technologies requires extensive optimization.
• Sample Size Constraints: Koya's supportive IIT data comes from a very small cohort (4 ALS patients, 9 FTD patients), necessitating confirmation in the larger 120+ patient Phase 2 trial.

Management Commentary and Tone:

• Tone: Highly optimistic and confident, emphasizing "robust" preclinical data, "eye-opening" clinical stability in small cohorts, and a "best-in-class" potential for shuttle delivery.
• Strategy: Management stresses the importance of combination therapies (Koya) and genetically validated metabolic targets (Leo) to address the limitations of single-agent approaches in a historically difficult field.
• Patient Focus: Emphasis on targeting the "diagnosis window" (ALS-FRS ~33-35) to stabilize patients before severe motor decline occurs.

Analyst Questions and Answers:

• Leo on NHP Data: Clarified that NHP studies focus on safety, target engagement, and PK/PD for shuttle delivery (MAPT, APOE) rather than full disease modeling, citing strong human genetic data as the primary validation driver.
• Leo on Toxicity: Addressed concerns regarding active Fc regions in shuttle antibodies; confirmed optimization efforts to avoid reticulocyte toxicity while maintaining phagocytosis-promoting function.
• Koya on FTD: Confirmed FTD trial initiation in 2027 following FDA clearance; noted preliminary data showed stability in MOCA scores and increased T-reg function.
• Koya on Trial Design: Explained the "All-Stars" Phase 2 design includes a 6-month primary endpoint, a 6-month open-label extension for the placebo arm, and stratification by NFL to ensure patient selection of those capable of responding.

Other Key Points:

• Biomarker Validation: Both companies highlight the validation of Neurofilament Light Chain (NFL) as a key biomarker, drawing parallels to the success seen with Tofersen and the FUS program.
• Self-Administration: Koya's COYA-302 is subcutaneous and low-dose, positioning it for eventual patient self-administration, a key logistical advantage over intrathecal therapies.
• Sporadic Focus: Both firms are uniquely positioned to address the 97-98% of ALS cases that are sporadic (non-genetic), unlike existing approved therapies restricted to rare mutations.
• Technology Synergy: Discussion highlighted the potential for Leo's shuttle platform to deliver various cargo types (sRNA, antibodies) including potential future collaborations or expansions.